Human epidemiological data presents mixed results, though some studies indicate correlations between elevated IGF-1 levels and increased risk of certain cancers, particularly breast, prostate, and colorectal cancers
This blend allows researchers to track steady-state data across multiple regulatory mechanisms simultaneously without requiring multi-vial cross-contamination risks
This dual-mechanism approach enables more pronounced and sustained growth hormone secretion than either peptide administered individually, while preserving the natural pulsatile pattern of growth hormone release that maintains physiological feedback mechanisms
The trade-off: Ipamorelin preserves natural GH pulsatility and is suitable for long-term protocols (12+ weeks), while MK-677 suppresses endogenous pulses through negative feedback and is best reserved for short 46 week maximum stimulus cycles
Usually, the higher the blood glucose level, the less GH and IGF-1 are produced
Blood-glucose caution: IGF-1 LR3 has insulin-like activity and can lower blood sugar